Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449605 · ClinicalTrials.gov registry record · Phase 3
A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 508
- Enrollment target
NCT00449605 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 508 participants.
The verdict
NCT00449605, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 508 participants
- Enrollment target
Study Summary
The primary objective is to demonstrate, after 52 weeks of treatment, the non-inferiority of rimonabant 20 mg once daily (od) versus glimepiride od in reducing glycosylated haemoglobin (HbA1c) in overweight/obese patients with type 2 diabetes not adequately controlled with metformin at a stable dose (≥ 1500 mg/day) for at least 3 months. The main secondary objectives are to assess the effect of rimonabant in comparison with glimepiride on body weight and HDL-Cholesterol and the long-term safety and tolerability of rimonabant in comparison with glimepiride.
Interventions
- DRUG Metformin
- DRUG Glimepiride
- DRUG Rimonabant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00449605
The ClinicalTrials.gov registry entry for NCT00449605 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00449605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00449605 about?
NCT00449605 is a clinical study titled "A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes". The primary objective is to demonstrate, after 52 weeks of treatment, the non-inferiority of rimonabant 20 mg once daily (od) versus glimepiride od in reducing glycosylated haemoglobin (HbA1c) in overweight/obese patients with type 2 diabetes not adequately controlled with metformin at a stable dose...
What is the current status of trial NCT00449605?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2007-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00449605?
The interventions under investigation include: Metformin (DRUG), Glimepiride (DRUG), Rimonabant (DRUG).
Who is sponsoring clinical trial NCT00449605?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.